553 related articles for article (PubMed ID: 32176643)
1. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.
Renard D; Wacongne A; Ayrignac X; Charif M; Fourcade G; Azakri S; Le Floch A; Bouly S; Marelli C; Arquizan C; Hirtz C; Gabelle A; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016; 50(3):759-764. PubMed ID: 26757185
[TBL] [Abstract][Full Text] [Related]
3. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
[TBL] [Abstract][Full Text] [Related]
4. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S
J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
[TBL] [Abstract][Full Text] [Related]
6. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
7. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy.
Li YF; Ge FF; Zhang Y; You H; Zhang ZX
Chin Med Sci J; 2015 Sep; 30(3):170-3. PubMed ID: 26564416
[TBL] [Abstract][Full Text] [Related]
10. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
De Kort AM; Kuiperij HB; Marques TM; Jäkel L; van den Berg E; Kersten I; van Berckel-Smit HEP; Duering M; Stoops E; Abdo WF; Rasing I; Voigt S; Koemans EA; Kaushik K; Warren AD; Greenberg SM; Brinkmalm G; Terwindt GM; Wermer MJH; Schreuder FHBM; Klijn CJM; Verbeek MM
Ann Neurol; 2023 Jun; 93(6):1173-1186. PubMed ID: 36707720
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.
Renard D; Gabelle A; Hirtz C; Demattei C; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016 Oct; 54(4):1291-1295. PubMed ID: 27567848
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
[TBL] [Abstract][Full Text] [Related]
13. Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease.
Noguchi-Shinohara M; Komatsu J; Samuraki M; Matsunari I; Ikeda T; Sakai K; Hamaguchi T; Ono K; Nakamura H; Yamada M
J Alzheimers Dis; 2017; 55(3):905-913. PubMed ID: 27802236
[TBL] [Abstract][Full Text] [Related]
14. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
De Kort AM; Kaushik K; Kuiperij HB; Jäkel L; Li H; Tuladhar AM; Terwindt GM; Wermer MJH; Claassen JAHR; Klijn CJM; Verbeek MM; Kessels RPC; Schreuder FHBM
Alzheimers Res Ther; 2024 May; 16(1):99. PubMed ID: 38704569
[TBL] [Abstract][Full Text] [Related]
15. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
[TBL] [Abstract][Full Text] [Related]
16. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.
Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Boulanghien J; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Perret-Liaudet A; Touchon J; Lehmann S
J Alzheimers Dis; 2011; 26(3):553-63. PubMed ID: 21709372
[TBL] [Abstract][Full Text] [Related]
17. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.
Piazza F; Greenberg SM; Savoiardo M; Gardinetti M; Chiapparini L; Raicher I; Nitrini R; Sakaguchi H; Brioschi M; Billo G; Colombo A; Lanzani F; Piscosquito G; Carriero MR; Giaccone G; Tagliavini F; Ferrarese C; DiFrancesco JC
Ann Neurol; 2013 Apr; 73(4):449-58. PubMed ID: 23625526
[TBL] [Abstract][Full Text] [Related]
18. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
19. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
20. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
